Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261642 | 0.85 | OPRD1 (0.56) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL10258162 | 0.79 | OPRD1 (0.66) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL471197 | 0.79 | OPRD1 (0.73) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| Hydrochloric Acid SCHEMBL1236204 | 0.78 | OPRD1 (0.64) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL21408598 | 0.73 | MAPT (0.49) | MAPT | |
| SCHEMBL471415 | 0.73 | OPRD1 (0.58) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL471409 | 0.71 | OPRD1 (0.53) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL471293 | 0.71 | OPRD1 (1.00) | OPRD1KCNH2OPRK1CYP2D6OPRM1 | |
| SCHEMBL10560264 | 0.71 | HDAC3 (0.41) | OPRD1KCNH2OPRK1MAPTOPRM1 | |
| SCHEMBL3411611 | 0.71 | HTR2C (0.69) | OPRD1KCNH2OPRK1MAPTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |